FDA
-
-
-
-
-
-
-
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
-
-
-
-
-
-
-
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
-
-
-
-
-
-
-
Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. FDA
-
-
-
-
-
-
-
The European Commission refers lecanemab decision to Appeal Committee
-
-
-
-
-
-
-
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
-
-
-
-
-
-
-
Leqembi revenue more than doubled - totaled JPY 6.3 billion in the second quarter 2024
-
-
-
-
-
-
-
Leqembi® (lecanemab) launched in China
-
326,134 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

